Form 4: Omnicell Director Mark W. Parrish Receives Restricted Stock Grant as Board Compensation

Omnicell, Inc. Director Mark W. Parrish was granted 6,828 shares of common stock as part of his compensation for services as a Board Member, aligning his interests with shareholders.

Summary

• Mark W. Parrish, a Director of Omnicell, Inc. (OMCL), acquired 6,828 shares of common stock on June 1, 2025.
• The acquisition was a grant of restricted shares under the Issuer's equity incentive plan, specifically for services as a Board Member pursuant to the Issuer's Board of Directors Compensation Plan.
• The granted shares will vest in full on the one-year anniversary of the grant date, which is June 1, 2026.
• Following this transaction, Mr. Parrish directly beneficially owns a total of 65,255 shares of Omnicell common stock.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates routine corporate governance and compensation practices that align director interests with shareholders, without any negative implications.

Positives

• The grant of restricted shares to a director aligns the director's financial interests with those of the company's shareholders, promoting long-term value creation.
• This transaction is part of a pre-established Board of Directors Compensation Plan, indicating a structured approach to executive and board remuneration.

Future Outlook

The granted restricted shares are scheduled to vest in full on June 1, 2026, subject to continued service as a Board Member.

Management Comments

• The grant was made in consideration of services as a Board Member pursuant to the Issuer's Board of Directors Compensation Plan.

Industry Context

The practice of granting restricted stock to board members as part of their compensation is a common and widely accepted practice across various industries, including healthcare technology, to attract and retain qualified directors and align their interests with long-term company performance.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) or similar equity awards to non-employee directors is a standard compensation practice in publicly traded companies, including those in the healthcare technology sector like Omnicell.
• The vesting schedule of one year is typical for such grants, aiming to retain directors and incentivize long-term commitment.
• While specific grant sizes vary by company size, industry, and individual director responsibilities, the mechanism of equity compensation for board service is consistent with global benchmarks for corporate governance and compensation.

Corporate Governance

Related Party Transactions

• The grant of 6,828 restricted shares to Mark W. Parrish, a Director of Omnicell, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to more shareholder-friendly decisions and long-term value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The 6,828 restricted shares granted to Mark W. Parrish are expected to vest in full on June 1, 2026.

Key Dates

Keywords

Omnicell, OMCL, Form 4, Insider Transaction, Stock Grant, Restricted Stock, Director Compensation, Equity Incentive Plan, Corporate Governance